Research and development daily Yan Jian submitted an application for the listing of the Alzheimer's treatment drug aducanumab.

the cornerstone pharmaceutical reT inhibitor China NSCLC research reached expectations; Lynparza was approved by the European Union for first-line maintenance treatment of BRCA mutant pancreatic cancer; and the treatment of bald concert innovative oral inhibitors was recognized by the FDA for breakthrough therapyWe focus on the latest developments in pharmaceutical research and development, to provide research and development personnel with timely and accurate information referenceCornerstone Pharmaceuticals today released the results of the Chinese patient study of the key worldwide I/II ARROW trial, RET inhibitor PralsetinibThe study data showed that Pralsetinib had superior and long-lasting clinical anti-tumor activity and good tolerance in RET-positive NSCLC patients in ChinaCinda Biopharmaceuticals today announced that Cindy Singli singroditi combined with Sofantini's Phase Ib clinical study has completed the first patient administration in ChinaThe study is a Phase Ib clinical study conducted in China to evaluate Sindi-Singli mitresadini-combined sofantinib treatment of subjects with advanced malignancies," the company announced, with its adhesive plaque kinase (FAK) inhibitor IN10018 single drug and combined chemotherapy second-line and post-line treatment of advanced gastric or gastroesophageal (GEJ) adenocarcinoma (GEJ) adenocarcinoma phase I clinical trial has completed the first patient administration at Tongji University affiliated Oriental Hospital in ShanghaiOn August 8, Mercado and Aishi announced that the U.SFDA had sent a complete response letter to the two companies' applicationfors for accelerated approval of Keytruda and Lenvima for first-line treatment in patients with non-removable hepatoblastomaAstraZeneca and Mercado announced Wednesday that Lynparza, a PARP inhibitor developed and commercialized by the two sides, has been approved by the European Union for first-line maintenance treatment in patients with metastatic pancreatic cancer with brcA mutations in the reproductive system, who have not progressed after at least 16 weeks of first-line chemotherapytoday, Yan Jian and Aishi jointly announced that Yan Jian has completed the application to the U.SFDA for a biologics license application, seeking approval for the treatment of Alzheimer's disease in the research drug aducanumabConcert today announced that the U.SFDA has awarded the company's oral Janus kinase (JAK) inhibitor CTP-543 breakthrough therapy for the treatment of patients with moderate to severe bald adultson the 9th of, Zeyi Pharmaceuticals issued a notice that it had recently received the "Notice of Clinical Trials" approved by the State Drug AdministrationThis approved to carry out toluene sulfonate Donafini tablets, Trepri sing-injection combined with catheter artery chemotherapy embolism treatment can not be surgically removed liver cell carcinoma the official website of the State Drug Administration, "July 08, 2020 drug notice pending release information" shows that Green Valley Pharmaceutical sly sugar diacid capsule (CXHS180038) listing application, was not approved The corresponding specification of this acceptance number is 450mg 8, Osekang announced that its independent research and development, with independent intellectual property rights of the anti-tumor biological drug "ASKB589 injection" approved clinical, intended for CLND18.2 positive local late or metastatic gastric and gastric esophagus binding adenocarcinoma, pancreatic cancer and other malignant solid tumors today, CDE announced that Henan Real Biotech has submitted a listing application for a new antiviral class 1 drug, azvudine, in China, the first new drug listing application submitted by Real Bio since its inception Today, Kiadis Pharma, which is dedicated to the development of innovative natural killing (NK) cell therapy, announced that it has entered into a research and development license agreement with Sanofi to grant Sanofi an exclusive research and development license for kiadis's previously undisclosed K-NK004 project.